NCT02677324 · OUTCOME

Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0

Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia · Source last updated 2022-05-11

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

What was measured

Number of participants who experienced an adverse event while on ABT-199

ABT199 will be administered daily, with 28 consecutive days defined as a treatment cycle for a maximum for 26 cycles ABT199: Oral BCL-2 antagonist

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
ABT199	33

Source class 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
ABT199	33	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

denoms

description

Number of participants who experienced an adverse event while on ABT-199

groups

param Type

COUNT_OF_PARTICIPANTS

reporting Status

POSTED

time Frame

2 years

title

Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0

type

SECONDARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice